Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,227 recruiting studies in this area right now.
By phase
- Not applicable3,140
- Phase 21,067
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4236
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis342
- Multiple Myeloma333
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes132
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona140
- New York122
- Massachusetts119
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,227 total
- NCT04517656Recruiting
Testing blood markers after a bone marrow donor transplant
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Saint-EtienneAges 18 years+ - NCT04022239RecruitingPhase 1/Phase 2
Bendamustine to prevent transplant immune complications
This early-phase study tests whether giving the drug bendamustine (with or without another chemo drug) can lower the risk of graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is an immune reaction where the donor’s cells attack your body. If it works and is safe, it could improve outcomes after transplant.
Houston, TexasAges 18–70 - NCT03057860Recruiting
Registry study for moderate to severe atopic dermatitis in Germany
This study is a national registry that collects information from people with moderate-to-severe atopic dermatitis (eczema). It helps doctors understand what treatments are used and how patients are doing over time.
Hanover, Lower SaxonyAges Any age - NCT03040583Recruiting
Study of people with primary Sjögren’s syndrome
This study follows adults with primary Sjögren’s syndrome. It may help researchers understand the condition better by using information from people who have already joined the earlier ASSESS study.
Le Kremlin-Bicêtre, Val De MarneAges 18 years+ - NCT02445222RecruitingPhase 3
Follow-up study for people treated with CAR-T therapy
This study checks how people do over the long term after receiving CAR-T, an advanced immune treatment. It may help doctors understand long-term safety and benefits, and what to expect after treatment.
Phoenix, ArizonaAges birth–100 years - NCT04869436RecruitingPhase 4
Dupilumab to improve smell in nasal polyps
This trial studies whether dupilumab can improve smell in adults whose nasal polyps are causing long-lasting smell loss. It may help learn how well the treatment restores smell, so future patients can benefit sooner.
London, OntarioAges 18 years+ - NCT02310867RecruitingPhase 2
Immunotherapy to help grafts heal for people with limb loss
This Phase 2 study tests an immune-targeting treatment to help a transplanted tissue “graft” integrate and heal better after limb loss. It may help by reducing problems with healing and rejection, but you must be able to complete frequent follow-up visits and testing.
Durham, North CarolinaAges 18–65 - NCT04837339Recruiting
Testing markers to predict problems after lung transplant
This study looks for lab “clues” that can help predict how well someone’s lungs will do after a lung transplant. It may help doctors spot transplant-related problems earlier so care can be planned sooner.
SuresnesAges 15 years+ - NCT05008965RecruitingPhase 2
Study drug for allergic asthma in adults
This Phase 2 trial tests whether FB825 can improve symptoms and safety in adults with moderate-to-severe allergic asthma. It is mainly for people whose asthma is not well controlled despite regular inhaler treatment.
Kaohsiung CityAges 18–75 - NCT05098171RecruitingEarly Phase 1
Study TIL cell therapy for advanced gynecologic cancers
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04517838Recruiting
Testing immune responses to anti-HER2 breast cancer treatments
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
Jacksonville, FloridaAges 18 years+ - NCT04056533RecruitingPhase 2
Preventing CMV after a haploidentical stem cell transplant
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
SantanderAges 18–80 - NCT03875703Recruiting
Biology sample collection after routine vaccination
This study collects biological samples (like blood and/or other samples) after you get a routine vaccine. It helps researchers learn more about how vaccines affect the body.
CréteilAges 18 years+ - NCT04571203RecruitingPhase 1
Kidney transplant plus blood-cell treatment to help the graft settle
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Palo Alto, CaliforniaAges 18–65 - NCT04197232Recruiting
Safety study of biologics in pregnancy for newborns
This trial looks at whether biologic medicines used during pregnancy are safe for the baby after birth. If your baby was born to a mother taking a biologic for an autoimmune disease, this study may be trying to track and confirm newborn safety outcomes.
Milan, LombardyAges 1 day–12 years - NCT03882840RecruitingPhase 1/Phase 2
T-like NK cell therapy for cancers with low MHC-I
This early-stage trial tests a lab-made immune cell treatment (T-like NK cells) for advanced cancers that have low or missing MHC-I on their cells. Because the treatment aims to “re-activate” the immune system against these cancers, you may be eligible if your cancer matches this feature and you meet safety requirements.
Guangzhou, GuangdongAges 18 years+ - NCT04237675Recruiting
Study of MS relapses after surgery
This study looks at relapses (new or worsening MS symptoms) after surgery in people with multiple sclerosis (MS). It may help researchers understand what triggers relapse after surgery so better care can be planned.
Athens, AtticaAges 18–70 - NCT04373057RecruitingPhase 1/Phase 2
Prebiotic fiber to prevent gut inflammation after transplant
This early-phase study tests a prebiotic (galacto-oligosaccharide) to see if it can lower or prevent gut inflammation caused by acute graft-versus-host disease (acute GVHD) after a stem cell transplant. If you’re scheduled for an allogeneic transplant, participating may help researchers find safer ways to protect your gut.
Kansas City, KansasAges 18–80 - NCT04392401Recruiting
Study immune changes in adults during ICU stay for COVID-19
This study looks at how your immune system responds while you’re in the intensive care unit (ICU) for COVID-19. Researchers will collect samples early in the ICU stay to better understand immune changes during the illness.
BronAges 18 years+ - NCT04526431Recruiting
Tacrolimus dose study in early kidney transplant patients
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
Grenoble, Auvergne-Rhône-AlpesAges 18 years+ - NCT04239703Recruiting
Kidney transplant biopsy study using blood test clues
This study looks at kidney transplant patients who are getting a kidney biopsy for usual clinical reasons. It tests whether special blood test results (from a sample taken as part of the study) can help spot transplant kidney problems earlier or more accurately.
Tampa, FloridaAges Any age - NCT03918421Recruiting
IgM-MAG neuropathy study using immunoglobulin M treatment
This study looks at a treatment made from immune proteins (immunoglobulin M) to treat neuropathy caused by anti-MAG antibodies. It may help improve nerve symptoms in people with this specific type of nerve condition.
BronAges 18 years+ - NCT03955172Recruiting
Test of everolimus to reduce transplant rejection
This trial studies whether everolimus can improve outcomes for people whose kidney transplant biopsy shows signs of a specific type of immune attack. It focuses on patients without certain antibodies and with particular biopsy findings, aiming to prevent rejection-related injury while balancing medication side effects.
LyonAges 18 years+ - NCT04199403Recruiting
Study of complication risks in adults without a spleen
This study looks at what factors can predict complications in people who do not have a functioning spleen, and how often those complications happen over time. It may help clinicians better identify higher-risk patients and improve care.
AngoulêmeAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,227 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,696 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.